Anthony J. Ocon, Nananamibia Duffy
doi : 10.1002/acr2.11496
Juliet Aizer, Erika L. Abramson, Jessica R. Berman, Stephen A. Paget, Marianna B. Frey, Victoria Cooley, Ying Li, Katherine L. Hoffman, Julie A. Schell, Michael D. Tiongson, Myriam A. Lin, Lisa A. Mandl
doi : 10.1002/acr2.11505
Self-efficacy, the internal belief that one can perform a specific task successfully, influences behavior. To promote critical appraisal of medical literature, rheumatology training programs should foster both competence and self-efficacy for critical appraisal.
Adam Amlani, May Y. Choi, Katherine A. Buhler, Marie Hudson, Mark Tarnopolsky, Lauren Brady, Heinrike Schmeling, Mark G. Swain, Cory Stingl, Ann Reed, Marvin J. Fritzler
doi : 10.1002/acr2.11510
The rationale for this study was based on reports that valosin-containing protein (VCP) mutations are found in hereditary inclusion body myositis (IBM) and VCP was detected in rimmed vacuoles of sporadic IBM (sIBM) muscle biopsies.
Jacopo Ciaffi, Giancarlo Facchini, Stefano Bandiera, Carlotta Cavallari, Marco Miceli, Alessandro Gasbarrini, Francesco Ursini
doi : 10.1002/acr2.11492
Belinda J. Lawford, Kim L. Bennell, Michelle Hall, Thorlene Egerton, Fiona McManus, Karen E. Lamb, Rana S. Hinman
doi : 10.1002/acr2.11513
Julia K. Weiner, Tristin Smith, Claire K. Hoy, Cyrus Sarosh, Jacqueline A. Madison, Amala Ambati, Ajay Tambralli, Noah Peters, Corinne Packel, Kelsey Gockman, Yu Zuo, Emily M. Briceño, Vivek Nagaraja, Jason S. Knight
doi : 10.1002/acr2.11512
This study assessed patient-reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life.
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez-Guerrero, Anand C. Patel, Dana Parsons-Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
doi : 10.1002/acr2.11511
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in patients with active autoantibody-positive systemic lupus erythematosus (SLE).
Theodore Pincus, Juan Schmukler, Joel A. Block, Nicola Goodson, Yusuf Yazici
doi : 10.1002/acr2.11514
Naomi J. Patel, Xiaoqing Fu, Yuqing Zhang, John H. Stone
doi : 10.1002/acr2.11520
Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). A score assessing and quantifying patients’ baseline GC-related toxicity may be important to risk stratification and therapeutic decision-making in patients initiating immunosuppression.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟